About Artax
Advancing novel treatments for autoimmune diseases
We brought together deeply experienced leaders in the field of immunomodulation to realize the full potential of our first-in-class pipeline of Nck modulator candidates.
Our mission: transform the way T cell mediated autoimmune diseases can be addressed
Our mission: transform the way T cell mediated autoimmune diseases can be addressed
Management team
-
Rob Armstrong, Ph.D.
Chief Executive Officer -
Chris VanDeusen, Ph.D.
Chief Scientific Officer -
D. Scott Batty, Jr., M.D.
Chief Medical Officer -
Joe Suarez
Chief Financial Officer -
Maria Nichol, DPHIL, EPA, CPA
Chief Business Officer -
Andy Gagete, Ph.D.
Chief Operating Officer -
Shannon Dwyer
Director of in vitro biology -
Suzanne Crowley, MS, BSN
VP Clinical Operations
Board of directors
Scientific advisory board
Well-capitalized to deliver our clinical data
We are supported by strong investors who see a broad therapeutic potential in our first-in-class approach with Nck modulators.